KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2010.04

  -

  2011.03

  日本学術振興会特別研究員

• 2011.04

  -

  2013.03

  熊本大学医学部附属病院, 薬剤部, 薬剤師

• 2013.04

  -

  2017.03

  崇城大学　, 薬学部, 助教

• 2018.04

  -

  2021.03

  慶應義塾大学, 薬学部, 専任講師

• 2021.04

  -

  Present

  慶應義塾大学, 薬学部, 准教授

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2006.03

  Kumamoto University, 薬学部

  University, Graduated

• 2008.03

  Kumamoto University

  Graduate School, Completed, Master's course

• 2011.03

  Kumamoto University

  Graduate School, Completed, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士 (薬学), 熊本大学, 2011.03

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 薬剤師, 2006.04

Books 【 Display / hide 】

Books 【 Display / hide 】

• Carbon monoxide-bound Hemoglobin-Vesicles: Current facts and potential medical applications.

  Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M, World Scientific Publishing Co. Pte. Ltd., 2021.12

  Scope: Chapter 6.10.,  Contact page： 849-865

• ＤＤＳ先端技術の製剤への応用開発

  宗慶太郎, 田口和明, 技術情報協会, 2017

  Scope: 第6章6節 pp. 360-8

• Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses

  Taguchi K, Chuang VT, Yamasaki K, Otagiri M., Nova Science Publishers, Inc., 2015

  Scope: Chapter 4, pp. 69-89

• HUMAN SERUM ALBUMIN

  Taguchi K, Chuang VT, Otagiri M., 2013

  Scope: Chapter 20, pp. 401-15

• Acute Phase Proteins

  Taguchi K, Nishi K, Chuang VT, Maruyama T, Otagiri M., Intech, 2013

  Scope: Chapter 6, pp.139-62

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Elucidating the binding properties of methemoglobin in red blood cell to cyanide, hydrosulfide, and azide ions using artificial red blood cell

  Suzuki Y., Arakida Y., Sakai H., Enoki Y., Matsumoto K., Taguchi K.

  Toxicology and Applied Pharmacology （Toxicology and Applied Pharmacology)  481   116752 2023.12

  Research paper (scientific journal), Joint Work, Corresponding author, Accepted,  ISSN  0041008X

  　View Summary

  Methemoglobin (metHb), the oxidized form of hemoglobin, lacks the ability of reversible oxygen binding; however, it has a high binding affinity to toxic substances such as cyanide, hydrosulfide, and azide. This innate property of metHb offers the clinical option to treat patients poisoned with these toxins, by oxidizing the endogenous hemoglobin in the red blood cells (RBCs). The binding properties of naked metHb (isolated from RBC) with these toxins has been studied; however, the binding behaviors of metHb under the intracellular conditions of RBC are unclear because of the difficulty in detecting metHb status changes in RBC. This study aimed to elucidate the binding properties of metHb in RBC under physiological and poisoned conditions using artificial RBC, which was hemoglobin encapsulated in a liposome. The mimic-circumstances of metHb in RBC (metHb-V) was prepared by oxidizing the hemoglobin in artificial RBC. Spectroscopic analysis indicated that the metHb in metHb-V exhibited a binding behavior different from that of naked metHb, depending on the toxic substance: When the pH decreased, (i) the cyanide binding affinity of metHb-V remained unchanged, but that of naked metHb decreased (ii) the hydrosulfide binding affinity was increased in metHb-V but was decreased in naked metHb. (iii) Azide binding was increased in metHb-V, which was similar to that in naked metHb, irrespective of the pH change. Thus, the binding behavior of intracellular metHb in the RBC with cyanide, hydrosulfide, and azide under physiological and pathological conditions were partly elucidated using the oxidized artificial RBC.

  • Access to Document (DOI)

• Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.

  Yamada T, Ishimaru M, Shoji T, Tomiyasu H, Tochinai R, Taguchi K, Komatsu T

  ACS applied bio materials  2023.12

  Research paper (scientific journal), Joint Work, Accepted

  • Access to Document (DOI)

• Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept

  Tanaka Y., Tashiro S., Ikegami S., Enoki Y., Taguchi K., Matsumoto K.

  Anaerobe （Anaerobe)  84   102789 2023.12

  Research paper (scientific journal), Joint Work, Corresponding author, Accepted,  ISSN  10759964

  　View Summary

  Objectives: Teicoplanin is a potential antimicrobial candidate for Clostridioides difficile infection (CDI) treatment. However, the therapeutic potential of teicoplanin against severe CDI has not been clinically proven. In the present study, we investigated the efficacy of oral teicoplanin administration against severe CDI and the recurrence of severe CDI after teicoplanin treatment in a mouse model. Methods: A lethal CDI mouse model was established by colonizing the mice with C. difficile ATCC® 43255; they were orally administered teicoplanin (128 mg/kg/d) or vancomycin (160 mg/kg/d) for 10 d, 24 h after C. difficile spore challenge, and physiological and biological responses were monitored for 20 d after the initial antibiotic treatment. We also performed the in vitro time-kill assay and determined minimum inhibitory concentration (MIC), post-antibiotic effect, and toxin production with antibiotic exposure. Results: The therapeutic response (survival rates, body weight change, clinical sickness score grading, C. difficile load, and toxin titer in feces) of oral teicoplanin administration was comparable to that of oral vancomycin administration in the lethal CDI mouse model. Moreover, teicoplanin treatment suppressed the re-onset of diarrhea and re-increase in toxin titer 10 d after treatment compared with that by vancomycin treatment. In in vitro experiments, teicoplanin exhibited time-dependent antibacterial activity and possessed lower MIC and longer post-antibiotic effect than vancomycin against C. difficile. C. difficile toxin production was numerically lower with teicoplanin exposure than with vancomycin exposure. Conclusions: The results obtained from the present basic experiments could suggest that teicoplanin is a potential antibiotic for the treatment of severe CDI with recurrence-prevention activity.

  • Access to Document (DOI)

• Polysarcosine-Coated liposomes attenuating immune response induction and prolonging blood circulation

  Hu M., Taguchi K., Matsumoto K., Kobatake E., Ito Y., Ueda M.

  Journal of Colloid and Interface Science （Journal of Colloid and Interface Science)  651   273 - 283 2023.12

  Research paper (scientific journal), Joint Work, Accepted,  ISSN  00219797

  　View Summary

  Hypothesis: Liposomes coated with long polysarcosine (PSar) chains at a high density might enable long blood circulation and attenuate accelerated blood clearance (ABC) phenomenon. Experiments: In this study, we controlled the length (23, 45, 68 mers) and density (5, 10, 15 mol%) of PSar on liposomal coatings and, furthermore, investigated the effects of PSar length and density on the blood circulation time, biodistribution, immune response, and ABC phenomenon induction. Length-controlled PSar-bound lipids (PSar-PEs) were synthesized using a click reaction and inserted into bare liposomes at different combinations of chain lengths and proportions. Findings: Although all PSar-coated liposomes (PSar-lipos) had similar morphological, physical, and chemical properties, they had different blood circulation times and biodistribution, and exerted varied effects on the immune system. All PSar-lipos with different PSar length and density showed a similar anti-PSar IgM response. Liposomes modified with the longest PSar chain (68 mers) at a high density (15 mol%) showed the longest blood circulation time and, additionally, attenuated ABC phenomenon compared with PEG-lipo. The ex vivo analysis of the biodistribution of liposomes revealed that a thick PSar layer enhanced the blood circulation time of liposomes due to the reduction of the accumulation of liposomes in the liver and spleen. These findings provide new insights into the relationship between IgM expression and ABC phenomenon inhibition.

  • Access to Document (DOI)

• Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogs

  Okamoto W., Usui T., Hasegawa M., Kobayashi T., Fujisawa J., Taguchi K., Matsumoto K., Kohno M., Iwazaki M., Shimano S., Nagao I., Toyoda H., Matsumura N., Tomiyasu H., Tochinai R., Komatsu T.

  Scientific Reports （Scientific Reports)  13 （ 1 ） 9512 2023.12

  Research paper (scientific journal), Joint Work, Accepted

  　View Summary

  Veterinary medicine has made tremendous progress for domestic dogs, which are irreplaceable family members enriching human life. Nevertheless, no adequate supply system exists for their blood products. This study examined the synthesis, structure, safety, and efficacy of poly(2-ethyl-2-oxazoline)-conjugated porcine serum albumin (POx-PSA) as an artificial plasma expander for dogs. The aqueous POx-PSA solution showed moderately high colloid osmotic pressure and good blood cell compatibility. Actually, lyophilized powder stored for 1 year can regenerate into a homogeneous solution. The circulation half-life of POx-PSA in rats was 2.1-fold longer than that of naked PSA. Rats produced neither anti-PSA IgG antibody nor anti-POx IgG antibody, which suggests excellent immunological stealth properties of POx-PSA. Complete resuscitation of hemorrhagic shock in rats was achieved soon after injection of POx-PSA solution. Serum biochemistry tests and histopathological observations indicated no abnormality in the related organs. When POx-PSA was administered to dogs intravenously, (i) no serum biochemical or hematological alteration was observed, also (ii) no overt deterioration of animal health was observed. These results indicate that POx-PSA has potential as an artificial plasma expander for dogs.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of novel hydrogen sulfide donor based on methemoglobin

  Taguchi, Kazuaki

  福澤諭吉記念慶應義塾学事振興基金事業報告集 （福澤基金運営委員会)  2022

• DDS technology innovation strategy for the treatment of drug-resistant cancer

  Taguchi, Kazuaki

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2020

• Therapeutic effects of carbon monoxide-bound Hemoglobin-vesicles against disaster-related syndorme

  Taguchi, Kazuaki

  科学研究費補助金研究成果報告書 2019

• Preparation of lactofferin nanoparticle and its pharmaceutical application

  Taguchi, Kazuaki

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2018

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• The charm of protein for drug development

  Ishima Y., Taguchi K.

  Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 2 ) 139 - 140 2020.02

  ISSN  00316903

  • Access to Document (DOI)

• 細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用

  田口 和明

  YAKUGAKU ZASSHI 138   1381 - 1389 2018

  Article, review, commentary, editorial, etc. (scientific journal), Single Work

• Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.

  Taguchi K, Yamasaki K, Maruyama T, Otagiri M.

  J Funct Biomater. 8 ( 1 ) E11 2017

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

• The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.

  Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.

  J Pharm Sci. 106 ( 9 ) 2392 - 2400 2017

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

• TDMの落とし穴～偽陽性と偽陰性～.

  田口和明, 猿渡淳二, 平田憲史郎, 丸山徹.

  医療薬学 41 ( 4 ) 215 - 222 2015

  Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 良質な薬物治療を目指したアカデミア創薬・育薬研究

  田口和明

  日本薬学会第144年会, 

  2024.03

  , 

  Symposium, workshop panel (nominated)

• ヘモグロビン小胞体投与が薬物動態関連タンパク質に与える影響

  田口和明、酒井宏水、松元一明、小田切優樹

  第30回 日本血液代替物学会 年次大会, 

  2023.12

  , 

  Symposium, workshop panel (nominated)

• セルフメディケーション税制に対する理解度と意識の実態調査

  田口和明

  医療経済研究会, 

  2023.07

  , 

  Public lecture, seminar, tutorial, course, or other speech

• 一酸化炭素結合型ヘモグロビン小胞体の薬剤誘発性臓器傷害に対する抑制効果

  田口和明、酒井宏水、小田切優樹、松元一明

  第29回日本血液代替物学会, 

  2022.12

  , 

  Symposium, workshop panel (nominated)

• 長期備蓄を目指した凍結乾燥粉末化メトヘモグロビン-アルブミンクラスター

  田口和明、鈴木悠斗、岡本航、小松晃之、松元一明

  第29回日本血液代替物学会, 

  2022.12

  , 

  Symposium, workshop panel (nominated)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• ヘモグロビンを基盤とした次世代型高感度ナノMRI造影剤の開発

  2022.06

  -

  2025.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, 挑戦的研究（萌芽）, Principal investigator

• サイトカインストーム制圧を目指したマクロファージ標的化一酸化炭素ナノ供与体の創製

  2022.04

  -

  2026.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, 基盤研究(B), Principal investigator

• ヘモグロビン内封リポソームを用いたシアン化物中毒解毒剤の開発

  2019.04

  -

  2021.03

  橋渡し研究戦略的推進プログラム　シーズA, Other, Principal investigator

• 震災特有疾患に対する一酸化炭素結合型ヘモグロビン小胞体の医薬品としての有用性評価

  2017.04

  -

  2020.03

  MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

• 一酸化炭素結合ヘモグロビン小胞体の多機能型蘇生剤としての有用性評価

  2014.04

  -

  2017.03

  科学研究費補助金・若手研究B, Research grant, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide 】

Intellectual Property Rights, etc. 【 Display / hide 】

• メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

  Date applied： 特願2020-144044,PCT/JP2021/ 31458  2020.08 

  Patent, Joint

• 横紋筋融解症治療剤

  Date issued： 特許第6523842号  2019.05

  Patent, Joint

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 熊本大学学長賞

  2011.03

• 日本薬学会九州支部学術奨励賞

  2017.12

• 日本薬学会奨励賞

  2020.03

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 日本DDS学会奨励賞 (臨床)

  2021.06, 日本DDS学会

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 日本薬物動態学会奨励賞

  2021.11, 日本薬物動態学会

  Type of Award： International academic award (Japan or overseas)

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

  2024

• SEMINAR (PHARMACODYNAMICS)

  2024

• RESEARCH FOR BACHELOR'S THESIS 1

  2024

• PRIOR LEARNING FOR CLINICAL PRACTICE 1

  2024

• PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

  2024

display all >>